JPWO2019016680A5 - - Google Patents

Info

Publication number

JPWO2019016680A5

JPWO2019016680A5 JP2020502118A JP2020502118A JPWO2019016680A5 JP WO2019016680 A5 JPWO2019016680 A5 JP WO2019016680A5 JP 2020502118 A JP2020502118 A JP 2020502118A JP 2020502118 A JP2020502118 A JP 2020502118A JP WO2019016680 A5 JPWO2019016680 A5 JP WO2019016680A5

Authority

JP

Japan

Prior art keywords

composition

seq

self

rna

nucleic acid

Prior art date

2022-05-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims description 42
• 239000000427 antigen Substances 0.000 claims description 14
• 102000036639 antigens Human genes 0.000 claims description 14
• 108091007433 antigens Proteins 0.000 claims description 14
• 150000007523 nucleic acids Chemical group 0.000 claims description 14
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
• 150000002632 lipids Chemical class 0.000 claims description 7
• 241000700605 Viruses Species 0.000 claims description 6
• 108020004707 nucleic acids Proteins 0.000 claims description 6
• 102000039446 nucleic acids Human genes 0.000 claims description 6
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 201000010099 disease Diseases 0.000 claims description 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
• 230000028993 immune response Effects 0.000 claims description 4
• 230000001939 inductive effect Effects 0.000 claims description 4
• 239000002105 nanoparticle Substances 0.000 claims description 4
• 102000003886 Glycoproteins Human genes 0.000 claims description 3
• 108090000288 Glycoproteins Proteins 0.000 claims description 3
• 229940022005 RNA vaccine Drugs 0.000 claims description 3
• 239000002671 adjuvant Substances 0.000 claims description 3
• 239000012634 fragment Substances 0.000 claims description 3
• 230000002163 immunogen Effects 0.000 claims description 3
• 229920001184 polypeptide Polymers 0.000 claims description 3
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 2
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 2
• 108060003393 Granulin Proteins 0.000 claims description 2
• 102000007999 Nuclear Proteins Human genes 0.000 claims description 2
• 108010089610 Nuclear Proteins Proteins 0.000 claims description 2
• 102000007982 Phosphoproteins Human genes 0.000 claims description 2
• 108010089430 Phosphoproteins Proteins 0.000 claims description 2
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
• 108020004705 Codon Proteins 0.000 claims 1
• 238000000034 method Methods 0.000 description 10
• 239000013598 vector Substances 0.000 description 8
• 108091026890 Coding region Proteins 0.000 description 4
• 108020004414 DNA Proteins 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000004530 micro-emulsion Substances 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 1
• 102000011931 Nucleoproteins Human genes 0.000 description 1
• 108010061100 Nucleoproteins Proteins 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• -1 constructs Substances 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 239000003814 drug Substances 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 239000007908 nanoemulsion Substances 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000000126 substance Substances 0.000 description 1